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Background: The use of poor quality antimalarial medicines, including the use of non-
recommended medicines for treatment such as sulfadoxine-pyrimethamine (SP) mono-
therapy, undermines malaria control and elimination efforts. Furthermore, the use of
subtherapeutic doses of the active ingredient(s) can theoretically promote the emergence
and transmission of drug resistant parasites.
Methods: We developed a deterministic compartmental model to quantify the impact of
antimalarial medicine quality on the transmission of SP resistance, and validated it using
sensitivity analysis and a comparison with data from Kenya collected in 2006. We
modelled human and mosquito population dynamics, incorporating two Plasmodium fal-
ciparum subtypes (SP-sensitive and SP-resistant) and both poor quality and good quality
(artemether-lumefantrine) antimalarial use.
Findings: The model predicted that an increase in human malaria cases, and among these,
an increase in the proportion of SP-resistant infections, resulted from an increase in poor
quality SP antimalarial use, whether it was full- or half-dose SP monotherapy.
Interpretation: Our findings suggest that an increase in poor quality antimalarial use
predicts an increase in the transmission of resistance. This highlights the need for stricter
control and regulation on the availability and use of poor quality antimalarial medicines, in
order to offer safe and effective treatments, and work towards the eradication of malaria.
© 2017 KeAi Communications Co., Ltd. Production and hosting by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).idwifery, Department of Health Sciences, University of South Australia, Adelaide, 5001, Australia.
.au (A.R. Brock).
unications Co., Ltd.
roduction and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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The spread of antimalarial resistance is hampering malaria control and elimination efforts globally (Ambroise-Thomas,
2012; World Health Organization, 2010a). Poor quality antimalarials can be categorised into three main groups: falsified;
substandard; and degraded (WorldWide Antimalarial Resistance Network, 2010). Each of these can be a source of subther-
apeutic doses of the active ingredient(s), which promote the emergence and transmission of drug resistant parasites through
selection pressures (Barnes, Watkins, & White, 2008; Simpson et al., 2000; White et al., 2009). Falsified antimalarials are
those that are fraudulently made and typically contain an incorrect amount of active ingredient, incorrect active ingredient,
toxic substances, or no active ingredient. Substandard antimalarials are those made by licenced companies but use poor
manufacturing practices. Degraded antimalarials degrade from their initial quality due to inadequate storage conditions, such
as excessive heat. In addition, within poor quality antimalarials, we include those that are not recommended in the World
Health Organization (WHO) guidelines.
Approximately 30% of antimalarial medicines in Africa and Asia are considered to be falsified or substandard (Ambroise-
Thomas, 2012; Newton, Green, & Fernandez, 2009). The outcome for those receiving poor quality antimalarials ranges from
prolongedmalaria symptoms, unexpected side effects, financial strain due to loss of income or healthcare costs, or even death
(Ambroise-Thomas, 2012; Newton, Green, Fernandez, Day, &White, 2006; Tabernero, Fernandez, Green, Guerin, & Newton,
2014). In Kenya, prior to 2004, sulfadoxine-pyrimethamine (SP) had been recommended as first-line for treatment of malaria.
Due to increasing resistance to SP, stemming frommutations in the P. falciparum dihydrofolate reductase (DHFR) gene, which
affects pyrimethamine, and the dihydropteroate synthase (DHPS) gene, which affects sulfadoxine, Kenya adopted artemether-
lumefantrine (AL) as its first-line treatment in 2004. In 2001, WHO recommended the use of artemisinin-based combination
therapies (ACTs) as first-line policy (World Health Organization, 2010b). In December 2007, a report was produced surveying
the antimalarial medicines available in Kenya and their quality. The researchers identified a wide range of products on the
market, the majority of which were not in-line with the new national guidelines, and a high proportion were either un-
registered or of low quality (Ministry of Health Republic of Kenya, 2007).
The effect of antimalarial use on the transmission of resistance has beenmodelled previously (Hastings, 2006; Klein, 2014;
Koella& Antia, 2003;Mackinnon&Hastings,1998; Tchuenche, Chiyaka, Chan, Matthews,&Mayer, 2011). Notably, themodels
currently available do not take into account the quality or percentage of antimalarial active ingredient and its effect on
transmission. As summarised by Koella and Antia (2003), part of the issue preventing these resistance transmission models
from being developed and used is a lack of complete, comprehensive datasets for key parameters. Since their model was
published, work has been carried out to look at the effect of drug quality on resistance within mice (Huijben et al., 2010a,
2013) and the effect of treatment in humans with SP-resistant infections (Barnes, Little, et al., 2008; Mendez et al., 2007).
Here we develop a new model to explore the impact of antimalarial quality, defined as poor quality SP, as defined above,
and good quality AL, on the transmission of SP antimalarial resistance in Plasmodium falciparum. To assist in more realistic
parameterisation of the model, we applied themodel to Kenya in 2006, rather than Kenya being a focus for actual predictions.
The model assumes that low to moderate SP-resistance conferred by mutations in the DHFR gene, the target of pyrimeth-
amine, has already been established within both human and mosquito populations.2. Materials and methods
2.1. Model structure
We developed a deterministic compartmental model to explore the impact of antimalarial quality on the transmission of P.
falciparum SP resistance (Fig. 1). The model quantifies the transmission dynamics of SP-sensitive (denotedw) and SP-resistant
(denoted r) P. falciparum between female Anophelesmosquitoes and humans. The human-mosquito system is modelled using
ordinary differential equations (ODEs) (Eq. (A1), Appendix A1). Humans may be infected by SP-sensitive strains ðwÞ, SP-
resistant strains ðrÞ, or both ðwrÞ. Resistance to SP was defined as the presence of DHFR-51 and DHFR-108 pyrimethamine
resistance-conferring mutations (Mendez et al., 2007), used as proxy for all low to moderate SP-resistant conferring muta-
tions in P. falciparum (Sridaran et al., 2010). At baseline, the percentage of humans andmosquitoes with SP-resistant infections
was set to 42% (Kum, Thorburn, Ghilagaber, Gil, & Bj€orkman, 2013; Spalding et al., 2010) and mixed infections was set to 8%
(Kum et al., 2013).
Humans free of P. falciparumwere classified as susceptible and denoted by SðHÞ. When transmission of sporozoites occurs
from female An.mosquitoes to humans during a blood meal, the human moves into the exposed class (EðHÞiÞ at the rate bH;i.
The script i indicates a SP-sensitive (i is w) or SP-resistant (i is r) P. falciparum infection. Due to the difference in the latent
periods for asexual P. falciparum and gametocytes, it is assumed that antimalarial treatment is sought while in the exposed
class to treat malaria symptoms as part of the asexual lifecycle (Poser & Bruyn, 1999). There are four types of treatment
available, each used as a proxy for ‘good quality’ or ‘poor quality’ treatments. Infected humans receive each treatment type
with probability qd, where the subscript d is q for a full dose of AL (good quality); m for a full-dose of SP monotherapy (poor
quality); p for a half-dose SP monotherapy (poor quality); and n for no treatment, either through no antimalarial compound
within the medicine sought or choosing not to seek treatment (poor quality). Following the gametocyte latency period, those
in the exposed class move into the infectious class at rate sH , which is assumed to be equal for both SP-sensitive and SP-
Fig. 1. A summary of the structure of the mathematical model showing the movement between compartments of SP-sensitive and SP-resistant Plasmodium
falciparum in humans and female Anopheles mosquitoes (blue solid line). The transmission of gametocytes (infected human to susceptible mosquito) and spo-
rozoites (infected mosquito to susceptible human) during a blood meal, is depicted by the red dotted line for SP-sensitive, and a dark green dotted line for SP-
resistant.
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mosquitoes are specified for each strain ði ¼ w; r or wrÞ and treatment ðd ¼ q;m; p or nÞ combination. The recovery rate is
defined by gi;d. Natural immunity is gained at rate gR, among thosewho do not receive treatment (Bousema&Drakeley, 2011),
and lost at rate r. The protective nature and rates for gaining and losing natural immunity are also assumed to be independent
of P. falciparum infection type.
Female Anophelesmosquitoes may be susceptible ðS Mð ÞÞ, exposed ðEðMÞiÞ, or infected ðIðMÞiÞ. Movement from susceptible
to an exposed class, after the transmission of P. falciparum during a bloodmeal, occurs at rate bM;i; where i isw for SP-sensitive
parasites or r for SP-resistant P. falciparum. The rate of transmission is defined as the product of the daily mosquito biting rate
ðcÞ and the probability of transmission given parasite strain and drug treatment received by the human (~Zw or ~Zr). We assume
that An. mosquitoes can only be infected by one strain of P. falciparum gametocytes (i.e., no mixed infections), and in the
occurrence that a susceptible mosquito feeds on a human host with a mixed infection, the probability of the SP-sensitive
strain being selected over the SP-resistant strain ðPwÞ and proceeding through the mosquito's midgut and onto the sali-
vary gland, is set at 0.6, assigning a relatively small fitness cost to resistance (Appendix D1). Following the latent period, the
mosquito enters the infectious class ðIðMÞiÞ at rate sM , and it is assumed that they do not recover from their infection due to
their short lifespans (Mandal, Sarkar, & Sinha, 2011). The parameters used in the model are defined in Tables 1 and 2.
Additional parameters, including details on the calculations of mosquito and human demographic turnover rates can be
found in Appendices BeE. The impact of SP on the level of gametocytes in humans has been extensively researched (Barnes,
Little, et al., 2008; Bousema & Drakeley, 2011; Mendez et al., 2007). We calculated an estimate for the length of gametocyte
carriage and the probability of transmission when treated with a full dose pyrimethamine, half dose (using 50% or 37.5% of a
full dose) of pyrimethamine, or no treatment (Huijben et al., 2010b, 2013, 2010a), and then calibrated these scenarios against
human SP monotherapy studies (Barnes, Little, et al., 2008; Mendez et al., 2007) (Appendix C2eC3).
The model simulations were run at the 2006 baseline level for all parameters, with the initial conditions (Appendix A2)
chosen to match surveillance data observed in Kenya in 2006. The system was solved for 1 year (2006), and the results
analysed. All analysis were carried out in Mathworks Matlab 2012a, using the ODE15s solver.
Table 1
Human Parameters. A summary of the model parameters used to calculate the rates of change in human movement (daily) between model compartments,
including: parameter definitions, symbols, parameter values used in the baseline model, and literature references or the section of the Appendices where the
parameters are defined.
Parameter description Symbol Value Reference
Human population size (initial) NH 1 Updated per iteration
Birth rate UH 1.1349  104 Appendix B1
Rate of humans becoming exposed to SP-sensitive sporozoites bH;w 0.0810 Appendix B2
Rate of humans becoming exposed to SP-resistant sporozoites bH;r 0.0810 Appendix B2
Rate of humans becoming infectious (gametocytes) sH 0.0556 Appendix B3
Receiving AL (proportion, at baseline) qq 0.70 Assumed, Appendix C1
Receiving full-dose SP monotherapy (proportion, at baseline) qm 0.07 Demographic and Health Surveys
(various), 2003e2012
Receiving full-dose SP monotherapy (proportion, at baseline) qp 0.03 Minzi et al. (2003); Newton et al.
(2006); Tabernero et al. (2014)
Receiving no treatment (proportion, at baseline) qn 0.20 Chuma et al. (2007)
Rate of human recovery from SP-sensitive P. falciparum having received AL gw;q 0.1667 Appendix B4
Rate of human recovery from SP-sensitive P. falciparum having received full-dose SP
monotherapy
gw;m 0.0588 Appendix B4
Rate of human recovery from SP-sensitive P. falciparum having received half-dose SP
monotherapy
gw;p 0.0476 Appendix B4
Rate of human recovery from SP-resistant P. falciparum having received AL gr;q 0.1667 Appendix B4
Rate of human recovery from SP- resistant P. falciparum having received full-dose SP
monotherapy
gr;m 0.0096 Appendix B4
Rate of human recovery from SP- resistant P. falciparum having received half-dose
SP monotherapy
gr;p 0.0096 Appendix B4
Rate of human recovery from mixed P. falciparum infection having received AL gwr;q 0.1667 Appendix B4
Rate of human recovery frommixed P. falciparum infection having received full-dose
SP monotherapy
gwr;m 0.0096 Appendix B4
Rate of human recovery from mixed P. falciparum infection having received half-
dose SP monotherapy
gwr;p 0.0119 Appendix B4
Rate of recovery having received no treatment gn 0.0149 Appendix B4
Overall transmission of SP-sensitive gametocytes (probability) ~Ζw 0.1459 Appendix D2
Overall transmission of SP-resistant gametocytes (probability) ~Ζr 0.1410 Appendix D2
Rate of acquired immunity gR 6.0864  104 Appendix B5
Rate of loss of acquired immunity r 0.0027 Labadin, Kon, & Juan (2009)
Rate of malarial mortality in humans mI 8.2880  104 Appendix B6
Rate of “other” mortality in humans mO 3.1779  105 Appendix B6
Table 2
Mosquito Parameters. A summary of the model parameters used to calculate the rates of change of movement (daily) of female An. mosquitoes between
model compartments, including: parameter definitions, symbols, parameter values used in the baseline model, and literature references or the section of the
Appendices where the parameters are defined.
Parameter description Symbol Value Reference
Ratio of An. mosquito to human population (initial) NM 0.87 Updated per iteration
Rate female An. mosquitoes reach adulthood UM 0.0280 Chitnisa, Hymanb, and Cushing (2008); Labadin et al. (2009)
Biting rate of female An. Mosquitoes c 0.4050 Anderson and May (1991); Mandal et al. (2011)
Rate of mosquitoes becoming exposed to SP-sensitive gametocytes bM;w 0.0591 Appendix E1
Rate of mosquitoes becoming exposed to SP-resistant gametocytes bM;r 0.0571 Appendix E1
Rate of mosquitoes becoming infectious (sporozoites at salivary gland) sM 0.2000 Appendix E2
Rate of mortality of female An. mosquitoes mM 0.0280 Mandal et al. (2011), Appendix E3
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The parameter values for the duration of gametocyte carriage and the probability a mosquito takes up a mature (infec-
tious) gametocyte during a bloodmeal, given the infection-type and treatment received by the patient, utilised a combination
of data frommicemalaria studies for pyrimethamine (Huijben et al., 2010b, 2013, 2010a) and human SP studies (Barnes, Little,
et al., 2008; Mendez et al., 2007). Pyrimethamine (not in combination with sulfadoxine) mice studies were used to inform
parameterisation due to the availability of data on pyrimethamine, with no such data was available on SP. This method is
described in Appendices C2eC3.
The expected duration of gametocyte carriage, given treatment scenarios, were calculated and compared to the 2006
baseline treatment level (70% AL use (assumed, Appendix C1), 7% full-dose SP monotherapy (Demographic and Health
Surveys (various), 2003e2012), 3% half-dose SP monotherapy (Minzi et al., 2003; Newton et al., 2006; Tabernero et al.,
2014), and 20% no treatment (Chuma, Gilson, & Molyneux, 2007)), in Fig. 2A and Table 3. An increase in the use of full-
dose or half-dose SP monotherapy use, or no treatment by 1% (with a corresponding 1% decrease in AL use), resulted in an
increase in the duration of gametocyte carriage from baseline (16.1 days) of 2½ hour, 3 h and 16 h, respectively. However,
AB C
Fig. 2. (A) The impact of antimalarial quality on the average duration of gametocyte carriage in humans. (BeC) The impact of antimalarial quality on the
infectiousness of humans to mosquitoes during a blood meal (probability), of (B) SP-sensitive and (C) SP-resistant gametocytes. Changes in the percentage use of
full-dose SP monotherapy (qm , orange line) were adjusted for the use of 3% half-dose SP monotherapy ðqpÞ, 20% receiving no treatment ðqnÞ and the remainder AL
treatment ðqqÞ. Likewise, changes in half-dose SP monotherapy use (qp, purple line) were adjusted for qm ¼ 7%; qn ¼ 20% and qq ¼ remainder; changes in those
receiving no treatment (qn, blue line) were adjusted for qm ¼ 7%; qp ¼ 3% and qq ¼ remainder; and changes in AL use (qq, green line) were adjusted for
qp ¼ 3%; qn ¼ 20% and qm ¼ remainder. The 2006 model baseline (black line) corresponds to qq ¼ 70%; qm ¼ 7%; qp ¼ 3% and qn ¼ 20%.
Table 3
The impact of changes in the percentage use of treatments (after 365 days), with percentage change, when compared to 2006model baseline for: the average
duration of gametocyte carriage; and the probability of mosquitoes taking up infectious gametocytes. The 2006 model baseline treatment use was set to 70%
AL treatment ðqqÞ, 7% full-dose SP monotherapy ðqmÞ, 3% half-dose SP monotherapy ðqpÞ and 20% no treatment ðqnÞ. Changes in the percentage use of full-
dose SPmonotherapy ðqmÞwere adjusted for qp ¼ 3%; qn ¼ 20% and qq ¼ remainder; changes in the use of half-dose SPmonotherapy use (qp) were adjusted
for qm ¼ 7%; qn ¼ 20% and qq ¼ remainder; changes in those receiving no treatment (qn) were adjusted for qm ¼ 7%; qp ¼ 3% and qq ¼ remainder; and
changes in AL use (qq) were adjusted for qp ¼ 3%; qn ¼ 20% and qm ¼ remainder. For exclusive use of a treatment (100% use), all other treatments were set to
0%.
Drug Use Scenarios Duration gametocyte carriage Probability infectious gametocytes
SP-sensitive SP-resistant
2006 model baseline 16.1 days 0.1459 0.1410
þ1% full-dose SP use þ2½ hours (0.6%) þ0.0016 (1.1%) þ0.0035 (2.5%)
þ1% half-dose SP use þ3 hours (0.8%) þ0.0008 (0.5%) þ0.0002 (0.1%)
þ1% no treatment þ16 hours (4.2%) þ0.0024 (1.6%) þ0.0021 (1.5%)
þ1% AL use  2 hours (0.5%)  0.0015 (1.0%)  0.0034 (2.4%)
100% full-dose SP use  3.3 days (20.4%) þ0.0951 (65.2%) þ0.2830 (200.7%)
100% half-dose SP use  1.6 days (10.2%) þ0.0178 (12.2%) 0.0498 (35.3%)
100% no treatment þ50.9 days (316.1%) þ0.1741 (119.3%) þ0.1390 (98.6%)
100% AL use 14.1 days (87.6%) 0.0600 (41.1%) 0.0658 (46.7%)
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baseline (3.3 days and 1.6 days, respectively); whereas increasing when no treatment is exclusively used by 50.9 days;
indicating no treatment has a large impact on carriage. In contrast, as the percentage of AL treatment increases, a decrease in
the average duration of gametocyte carriage is observed (2 h per 1% increase), down to an eventual duration of 2 days when
used exclusively.
The calculated probability of mosquitoes taking up infectious gametocytes during a blood meal also increased in response
to greater use of full- and half-dose SP monotherapy, and no treatment (Fig. 2BeC, Table 3). In settings where SP resistance is
already firmly established, a 1% increase in full-dose SP monotherapy resulted in a larger percentage increase in SP-resistant
infectiousness, than sensitive infectiousness (2.5% v 1.1%). This is further highlighted under the scenario of exclusive use of
full-dose SP, where results indicate a 200.7% increase in the probability of mosquitoes taking up SP-resistant P. falciparum,
compared to a 65.2% increase in SP-sensitive P. falciparum. In contrast, 1% increases in half-dose SP or no treatment use had a
greater percentage increase in the probability of mosquitoes taking up SP-sensitive P. falciparum (0.5% and 1.6%, respectively)
compared to SP-resistant P. falciparum (0.1% and 1.5%, respectively). However, when used exclusively, half-dose SP had the
greatest percentage increase in SP-resistant P. falciparum compared to SP-sensitive (35.3% v 12.2%); with exclusive use of no
treatment resulting in a similarly large percentage increase for both (98.6% and 119.3%, respectively). Changes in the use of AL
resulted in a greater decrease in the probability of SP-resistant P. falciparum being taken up by mosquitoes, compared to SP-
sensitive P. falciparum (2.4% v 1.0%, for 1% increase; and 46.7% v 41.1%, when exclusively used).
2.3. Measuring the effect on transmission
The main outcome of interest is the impact of antimalarial quality on the total proportion of SP-resistant infections
(resistant and mixed infections) in the human population (∅, Eq. (1)):
∅ ¼
P
XXðHÞwIðHÞrP
XIðHÞwXðHÞr þ
P
XXðHÞwIðHÞr  IðHÞwIðHÞr
(1)Here XðHÞ denotes the human classes (excluding acquired immunity), where the subscript w and r once again denote SP-
sensitive and SP-resistant P. falciparum, respectively.
In addition to the proportion of SP-resistant infections, we also measured the expected number of malaria cases in
humans.
2.4. Model accuracy
To validate our results, we performed a sensitivity analysis, and compared baseline model predictions against estimates
found in the literature. A one-way sensitivity analysis was carried out, where each parameter was individually changed to the
minimum and maximum value in its defined parameter range, and the change in the total proportion of SP-resistant in-
fections in the human population was calculated. Parameters that inferred a change of greater than ±10% were considered to
be significant during the sensitivity analysis.
3. Results
To quantify the impact of antimalarial quality on the transmission of SP resistance in P. falciparum, we varied the amount of
good and poor quality antimalarial use in the population. Any change in antimalarial use that assists the survival and
propagation of antimalarial resistance within human and mosquito populations highlights the need for better control and
regulations of the use and availability of these medicines in order to offer safe and effective treatment.
3.1. Malaria cases (human)
At baseline, our model predicts 10,807,000 malaria cases in Kenya during 2006 (Fig. 3A, Table 4). An increase in the use of
poor quality antimalarial use predicts a greater number of malaria cases, with the greatest increase observed under the
scenario of full-dose SP being exclusively used (776.9%), followed by no treatment (773.6%) and the exclusive use of half-dose
SP use (558.6%). This suggests that people may experience multiple malaria infections within one calendar year (population
size 36,757,498 (The World Bank., 2006e2013g)). Under the exclusive use of AL, the model predicts that the number of
malaria cases in Kenya for 2006 could have been 2,978,200 (a reduction of 72.5% from baseline). The proportion of malaria
cases that contained SP-resistant P. falciparum reflects these increases under each scenario of SP use, where exclusive use of
full-dose SP increases by 18.4% from baseline, and half-dose increases by 13.8% (Fig. 3B, Table 4). Decreases in the proportion
of SP-resistant infections were observed when no treatment was used (5.8%) and the exclusive use of AL (1.8%).
Fig. 3. (A) The impact of antimalarial quality on the predicted number of human malaria cases in 2006. (B) The impact of antimalarial quality on the total
proportion of SP-resistant infections in humans. Changes in the percentage use of full-dose SP monotherapy (qm , orange line) were adjusted for the use of 3% half-
dose SP monotherapy ðqpÞ, 20% receiving no treatment ðqnÞ, and the remainder AL treatment ðqqÞ. Likewise, changes in half-dose SP monotherapy use (qp, purple
line) were adjusted for qm ¼ 7%; qn ¼ 20%, and qq ¼ remainder; changes in those receiving no treatment (qn, blue line) were adjusted for qm ¼ 7%; qp ¼ 3% and
qq ¼ remainder; and changes in AL use (qq, green line) were adjusted for qp ¼ 3%; qn ¼ 20%, and qm ¼ remainder. The 2006 model baseline (black line) corre-
sponds to qq ¼ 70%; qm ¼ 7%; qp ¼ 3%, and qn ¼ 20%. Model simulations run for 365 days.
Table 4
The impact of changes in the percentage use of treatments (after 365 days) on the expected number of malaria cases in Kenya for 2006 and
the proportion of resistant infections (percentage change), when compared to the 2006 model baseline. The 2006 model baseline
treatment use was set to 70% AL treatment ðqqÞ, 7% full-dose SP monotherapy ðqmÞ, 3% half-dose SP monotherapy ðqpÞ, and 20% no
treatment ðqnÞ; and for the exclusive use of a treatment (100% use), all other treatments were set to 0%.
Drug Use Scenarios Expected malaria cases (2006) Proportion SP-resistant
2006 model baseline 10,807,000 0.8404
100% full-dose SP use þ83,964,000 (776.9%) þ0.1545 (18.4%)
100% half-dose SP use þ60,366,000 (558.6%) þ0.1157 (13.8%)
100% no treatment þ83,608,000 (773.6%) 0.0491 (5.8%)
100% AL use 7,831,300 (72.5%) 0.0148 (1.8%)
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Key 2006 baseline model output was compared to empirical estimates for the Kenyan population (Table 5), indicating our
model predicted these outputs within an acceptable range. For the sensitivity analysis, parameters that inferred a change in
the total proportion of SP-resistant infections in the human population of greater than ±10%were considered to be significant
(Table 6). As seen with other malaria models (Mandal et al., 2011), our model was sensitive to mosquito parameters, such as
the proportion of mosquitoes to humans, the daily rate female An. mosquitoes reach adulthood, and the probability of
transmission of SP-sensitive and SP-resistant sporozoites during a blood meal. Additionally, the expected gametocyte
clearances of SP-sensitive and SP-resistant gametocytes when treated with AL were found to significantly influence model
outputs. The full sensitivity analysis is available in Appendix F.
Table 5
Results validation. A comparison of the baseline model outcomes with literature estimates for 2006 and the published reference, including the percentage
error in the 2006 model estimate, for: the rate of population growth; the proportion of each strain of Plasmodium falciparummalaria in humans; the number
of P. falciparum cases of malaria in humans; and the human mortality (total and malaria-specific).
Description 2006 Model
Outcome
2006 Literature Value (Reference) Difference
(%)
Population growth, % (2006e2007) 2.7559 2.7 (The World Bank, 2006e2013b) 2
Malaria cases 10,857,000 8,926,058 (World Health Organization, 2010b) 22
Deaths (all) 500,980 404,332 (The World Bank, 2006e2013b) 24
Malaria-specific deaths 72,592 74,970 (The World Bank, 2006e2013b; World Health Organization,
2010b)
3
Proportion of SP-sensitive infections in humans
ðwÞ
0.1625 0.05e0.5 (Kum et al., 2013) Within
range
Proportion of SP-resistant infections in humans
ðrÞ
0.8356 0.42e0.90 (Kum et al., 2013; Spalding et al., 2010) Within
range
Proportion of mixed infections in humans ðwrÞ 0.0019 0e0.53 (Assumed) Within
range
Table 6
Sensitivity analysis summary. Results for the sensitivity analysis, where parameter range (minimum and/or maximum) resulted in a ±10% change in the
proportion of SP-resistant infections in humans. Full sensitivity analysis results are available in Appendix F. A Largest value we could get a numerical solution
for, actual literature range maximum value is 0.27.
Parameter Range (literature range or ±10%) Percentage change (%)
Baseline Minimum Maximum Minimum Maximum
Ratio of mosquito to human population (initial, humans ¼ 1) ðNMÞ 0.87 0.5 40 0.32 20.55
Rate female An. mosquitoes reach adulthood ðUMÞ 0.028 0.020 0.1406 A 0.26 36.20
SP-sensitive sporozoite transmission (probability) ðTwÞ 0.2 0.2 0.5 0.00 86.98
SP-resistant sporozoite transmission (probability) ðTrÞ 0.2 0.2 0.5 0.00 17.90
SP-sensitive gametocyte clearance in humans treated with AL ðεw;qÞ 14 7 28 9.20 13.61
SP-resistant gametocyte clearance in humans treated with AL ðεr;qÞ 14 7 28 15.52 8.65
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Our model suggests that once SP resistance is widespread, as was the case in Kenya in 2006, an increase in poor quality
antimalarial use (focusing on SP) results in an increase in: (i) the number of human malaria cases (Fig. 3A), and (ii) of these
cases, an increase in the proportion of SP-resistant infections in humans (full- or half-dose SP used, Fig. 3B), when compared
to good quality antimalarial use (AL). The predicted increase in malaria cases is of concern, where the scenario of full-dose SP
being exclusively used (þ776.9%), followed by no treatment (þ773.6%) and the exclusive use of half-dose SP use (þ558.6%),
yield large increases; whereas the exclusive use of AL results in a marked decrease in the number of expected cases (72.5%).
The predicted increase in resistant-containing infections under SP drug pressure is supported by findings from Hastings
(Hastings, 2006). Our findings suggest that a delay in P. falciparum clearance in humans, due to SP-resistance and/or inad-
equate antimalarial active ingredient, allows for prolonged transmission of SP-resistant gametocytes, hence ensuring their
propagation throughout human and mosquito populations.
There are clear examples of substandard SP circulating in east Africa and elsewhere (see http://www.wwarn.org/
aqsurveyor/#0). A common problem has been impaired drug dissolution due to poor manufacturing, despite having the
correct amounts of SP in the tablet, which result in low blood SP drug levels (Leslie et al., 2009; White et al., 2009). The
impacts described here for reduced dosage of SP will also apply to this situation of reduced bioavailability. In addition,
systematic under-dosing of antimalarials, common in pregnancy and young children, has been shown to impact efficacy, with
theoretical impacts of the selection of drug resistance (Barnes, Watkins,&White, 2008; Sambol et al., 2015). In all these cases,
the key variable will be the antimalarial levels parasites are exposed to, reflecting both antimalarial content and
bioavailability.
The impact of antimalarial quality on mortality could not be explicitly explored as the model assumes that the proportion
of malaria-specific mortality ðmIÞ is proportional to the prevalence of malaria and hence driven by this relationship. This
additionally acts to drive the overall mortality.
The accuracy of the model indicated larger percentage errors in the predicted malaria cases and malaria deaths for 2006
(Table 5). However, this simulated number of malaria cases is below the 15 million cases estimated to have occurred in Kenya
in 2006 (World Health Organization, 2010b), where under-reporting is considered a factor. This under-reporting is also
assumed for malarial deaths, where there are discrepancies between the estimated (overall) deaths in Kenya in 2006 (The
World Bank, 2006-2013c; World Health Organization, 2010b) (Appendix B6).
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combination of data frommice malaria studies for pyrimethamine (Huijben et al., 2010b, 2013, 2010a) and human SP studies
(Barnes, Little, et al., 2008; Mendez et al., 2007). The use of these calculated estimates introduces a margin of error; as well as
the possible under-estimation of the transmissibility and infectiousness of those receiving a half-dose of SP (Appendix C3.2).
The impact of antimalarial quality on the duration of gametocyte carriage seems plausible, with the largest increase predicted
from increases in those who receive no treatment. Increases in carriage duration were observed with increases in the per-
centage SP use, with half-dose SP monotherapy showing more marked increases in carriage duration than full-dose SP
monotherapy. This may be explained by SP-sensitive infections being cleared more slowly following sub-therapeutic con-
centrations of antimalarial medicine, then when using full-dose SP, thereby providing a longer period for gametocytes to
remain in circulation. Interestingly, this relationship was not observed when considering pyrimethamine-resistant game-
tocyte density in mice, despite peak density and carriage often being correlated (Huijben et al., 2013). The limitations in
approximating these parameters further highlight the need for more data in this area, as well as other more currently utilised
antimalarial drugs.
The model assumed that SP-resistance is conferred by mutations in the DHFR gene, omitting other possible mutations
conferring sulfadoxine-resistance, or other mutations in the DHFR gene such as C59R or the high level resistance-conferring
I15L mutation (Rosenthal, 2013). The selection of low to moderate SP resistance was due to the availability of data (or lack
thereof), highlighting the need for further research in this area.
It must be noted that both symptomatic and asymptomatic infections (Bousema, Okell, Felger,&Drakeley, 2014), as well as
those with acquired immunity (Klein, Smith, Boni, & Laxminarayan, 2008), harbour gametocytes. The transmission potential
of asymptomatic or acquired immune individuals were not included as a source of transmission, as they are outside of the
scope of this study. Additionally, the model parameterised the mortality of mosquitoes irrespective of infection-status; did
not allow mixed infections within the mosquito population; and a fitness-cost was assigned to SP-resistant gametocytes
whenmixed infections were taken up during a bloodmeal. Amore detailed discussion of these assumptions and limitations is
provided in Appendix G.
The effect of antimalarial treatment on gametogenesis and infectiousness differs depending on the antimalarial class. A
key assumption in using poor quality SP as a proxy for the use of all poor quality antimalarial use is that we assume that all
antimalarials have the same propensity to generate gametocytes and effect on gametocyte infectiousness, which is not the
case. For example, ACT use is associated with a lower rate of gametocyte carriage (Bousema & Drakeley, 2011), highlighting
the need for further studies.5. Conclusions
Themodel predicts that an increase in the use of poor quality antimalarials, for which SP is an appropriate proxy, results in
an increase in the transmission of antimalarial resistant malaria, providing insight into the link between poor quality anti-
malarial medicine use and resistance. The loss of antimalarial effectiveness is hampering malaria eradication efforts
worldwide, and the continued availability and use of falsified, substandard, degraded and non-WHO recommended anti-
malarials are highly likely to facilitate the spread of resistance. In order to continue to effectively eradicate malaria, the
availability and use of these antimalarials must be addressed by drug regulatory authorities and international organisations.Competing interests
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A1. Ordinary differential equations
dS Hð ÞwS Hð Þr
dt
¼ aH  NH  bH;w  S Hð ÞwS Hð Þr  I Mð Þw  bH;r  S Hð ÞwS Hð Þr  I Mð Þr þ I Hð ÞwS Hð Þr
h
qq  gw;q þ qm
 gw;m þ qp  gw;p þ qn  gn
i
þ qq  gwr;q  I Hð ÞwI Hð Þr þ S Hð ÞwI Hð Þr
h
qq  gr;q þ qm  gr;m þ qp
 gr;p þ qn  gn
i
þ r R Hð Þ  mO  S Hð ÞwS Hð Þr
dE Hð ÞwS Hð Þr h
dt
¼ bH;w  S Hð ÞwS Hð Þr  I Mð Þw  bH;r  E Hð ÞwS Hð Þr  I Mð Þr  sH  E Hð ÞwS Hð Þr þ E Hð ÞwI Hð Þr qq  gr;q
þ qm  gr;m þ qp  gr;p þ qn  gn
i
 mO  E Hð ÞWS Hð Þr
dI Hð ÞwS Hð Þr
dt
¼ sH  E Hð ÞwS Hð Þr  bH;r  I Hð ÞwS Hð Þr  I Mð Þr  I Hð ÞwS Hð Þr qq  gw;q þ qm  gw;m þ qp  gw;p þ qn
 gn

þ 1
2
 qn  gn  I Hð ÞwI Hð Þr  gR  I Hð ÞwS Hð Þr  mI  I Hð ÞwS Hð Þr
dSðHÞwEðHÞr h
dt
¼ bH;r  SðHÞwSðHÞr  IðMÞr  bH;w  SðHÞwEðHÞr  IðMÞw  sH  SðHÞwEðHÞr þ IðHÞwEðHÞr qq  gw;q
þ qm  gw;m þ qp  gw;p þ qn  gn
i
 mO  SðHÞwEðHÞr
dE Hð ÞwE Hð Þr
dt
¼ bH;w  S Hð ÞwE Hð Þr  I Mð Þw þ bH;r  E Hð ÞwS Hð Þr  I Mð Þr  2 sH  E Hð ÞwE Hð Þr  mO  E Hð ÞwE Hð Þr
dI Hð ÞwE Hð Þr h
dt
¼ bH;r  I Hð ÞwS Hð Þr  I Mð Þr þ sH  E Hð ÞwE Hð Þr  sH  I Hð ÞwE Hð Þr  I Hð ÞwE Hð Þr qq  gw;q þ qm  gw;m
þ qp  gw;p þ qn  gn
i
 gR  I Hð ÞwE Hð Þr  mI  I Hð ÞwE Hð Þr
dS Hð ÞwI Hð Þr h
dt
¼ sH  S Hð ÞwE Hð Þr  bH;w  S Hð ÞwI Hð Þr  I Mð Þw  S Hð ÞwI Hð Þr qq  gr;q þ qm  gr;m þ qp  gr;p þ qn
 gn
i
þ I Hð ÞwI Hð Þr

qq  gwr;q þ qm  gwr;m þ qp  gwr;p þ
1
2
 qn  gn

 gR  S Hð ÞwI Hð Þr  mI
 S Hð ÞwI Hð Þr
dE Hð ÞwI Hð Þr hdt
¼ bH;w  S Hð ÞwI Hð Þr  I Mð Þw þ sH  E Hð ÞwE Hð Þr  sH  E Hð ÞwI Hð Þr  E Hð ÞwI Hð Þr qq  gr;q þ qm  gr;m
þ qp  gr;p þ qn  gn
i
 gR  E Hð ÞwI Hð Þr  mI  E Hð ÞwI Hð Þr
dI Hð ÞwI Hð Þr h i
dt
¼ sH  E Hð ÞwI Hð Þr þ sH  I Hð ÞwE Hð Þr  I Hð ÞwI Hð Þr qq  gwr;q þ qm  gwr;m þ qp  gwr;p þ qn  gn  gR
 I Hð ÞwI Hð Þr  mI  I Hð ÞwI Hð Þr
dR Hð Þ
dt
¼ gR  ½I Hð ÞwS Hð Þr þ I Hð ÞwE Hð Þr þ I Hð ÞwI Hð Þr þ S Hð ÞwI Hð Þr þ E Hð ÞwI Hð Þr   r R Hð Þ  mO  R Hð Þ
dDðHÞI  
dt
¼ mI IðHÞwSðHÞr þ IðHÞwEðHÞr þ SðHÞwIðHÞr þ EðHÞwIðHÞr þ IðHÞwIðHÞr
dD Hð ÞO
dt
¼ mO½S Hð ÞwS Hð Þr þ E Hð ÞwS Hð Þr þ S Hð ÞwE Hð Þr þ E Hð ÞwE Hð Þr þ R Hð Þ 
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dt
¼ UM  NM  bM;w  S Mð Þ½I Hð ÞwS Hð Þr þ I Hð ÞwE Hð Þr þ Pw  I Hð ÞwI Hð Þr   bM;r  S Mð Þ½S Hð ÞwI Hð Þr
þ E Hð ÞwI Hð Þr þ ð1 PwÞ  I Hð ÞwI Hð Þr   mM  S Mð Þ
dEðMÞw  
dt
¼ bM;w  SðMÞ IðHÞwSðHÞr þ IðHÞwEðHÞr þ Pw  IðHÞwIðHÞr  sM  EðMÞw  mM  EðMÞw
dIðMÞw
dt
¼ sM  EðMÞw  mM  IðMÞw
dE Mð Þr
dt
¼ bM;r  S Mð Þ½S Hð ÞwI Hð Þr þ E Hð ÞwI Hð Þr þ ð1 PwÞ  I Hð ÞwI Hð Þr   sM  E Mð Þr  mM  E Mð Þr
dIðMÞr
dt
¼ sM  EðMÞr  mM  IðMÞr
dDðMÞ  
dt
¼ mM SðMÞ þ EðMÞw þ EðMÞr þ IðMÞw þ IðMÞr (A1)A2. Initial conditions
The set of initial conditions for each class of the model are defined in Table A2.1.Table A2.1
Initial Conditions. The initial values of each class in the model (i.e. when time is set to 0).
Population Model Class Initial Value ðt ¼ 0Þ
Human NH 1:0000
EðHÞwSðHÞr 0:0021
IðHÞwSðHÞr 0:0009
SðHÞwEðHÞr 0:0108
EðHÞwEðHÞr 0:0000
IðHÞwEðHÞr 0:0000
SðHÞwIðHÞr 0:0046
EðHÞwIðHÞr 0:0000
IðHÞwIðHÞr 0:0000
RðHÞ 0:0000
DðHÞI 0:0000
DðHÞO 0:0000
SðHÞwSðHÞr NH  ½EðHÞwSðHÞr þ IðHÞwSðHÞr þ SðHÞwEðHÞr þ EðHÞwEðHÞr þ IðHÞwEðHÞr
þSðHÞwIðHÞr þ EðHÞwIðHÞr þ IðHÞwIðHÞr þ RðHÞ þ DðHÞI þ DðHÞO

Mosquito NM 0:8700
EðMÞw 0:0002
EðMÞr 0:0012
IðMÞw 0:0017
IðMÞr 0:0088
DðMÞ 0:0000
SðMÞ NM  ½EðMÞw þ EðMÞr þ IðMÞw þ IðMÞr  DðMÞB. Human parameters
The model parameters for the human population are defined in Table B.1, along with the parameter values used, the
parameter range, and the published reference or the section of the Appendices where this parameter is defined.Table B.1
Human Parameters. A description of the parameters specific to the human population, in Kenya (2006). For parameter values where literature values were
readily available, these values, along with the range of values and references are provided. For parameters that required further manipulation from the
original source, the section of the Appendices where this parameter is discussed is noted. All parameter units are in days, unless otherwise stated.
Parameter description Symbol Value [range] Reference
Human Kenyan population (count) YK 36,757,498 The World Bank (2006e2013g)
Number of deaths in Kenya in 2006 (count) DK 11 per 1000 The World Bank (2006-2013c)
Births per year in Kenya c 38 per 1000 The World Bank (2006-2013a)
(continued on next page)
Table B.1 (continued )
Parameter description Symbol Value [range] Reference
Range of child-bearing ages (years of age): initial, final lI , lF 15, 49 Ikamari, Izugbara, and Ochako (2013)
Fertility rate (births per woman) z 4:9 The World Bank (2006-2013d)
Proportion of population that are female j 0.501 The World Bank (2006-2013f)
Life expectancy of humans (days) xH 20,454 The World Bank (2006-2013e)
Kenyan 2006 malaria cases (count) YM 8,926,058 World Health Organization (2010b)
Kenyan 2006 malarial deaths (count) DM 74,970 The World Bank (2006-2013c); World Health
Organization (2010b)
Latency period of asexual parasites in humans (days) PН 9 [9, 14] Bloland and Williams (2002)
Delay in seeking treatment (days) h 1 [0, 2] Sumba, Wong, Kanzaria, Johnson, and John (2008)
Time to initial wave of gametocytes after the initial wave of asexual
parasites (days)
GI 7 [7, 15] Bousema and Drakeley (2011)
Time for gametocytes to mature (days) GM 2 [2, 3] Bousema and Drakeley (2011)
Total time until infectious gametocytes (days) from time of transmission
from mosquito
y 18 [18, 32] Appendix B3
Rate of the loss of acquired immunity r 0.0027 Labadin et al. (2009)
Allele frequency of SP-sensitive P. falciparum Fw 0.50 [0.05,
0.50]
Kum et al. (2013)
Allele frequency of SP-resistant P. falciparum Fr 0.42 [0.42,
0.90]
Kum et al. (2013); Spalding et al. (2010)
Allele frequency of mixed P. falciparum Fwr 0.08 [0, 0.08] Kum et al. (2013)
The rate of building effective immunity q 27.3774 Labadin et al. (2009)
The rate of recovery of P. falciparum infection s 0.0018 Labadin et al. (2009)
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Equations B1.1 and B1.2 were used to calculate a parameter range for the daily birth rate of humans ðUНÞ, resulting
parameter range for daily birth rate of humans ðUНÞ was1:0411 104 -7:811 104.
UН ¼ c365 (B1.1)
z ¼ UН  j ðlF  lIÞ
xH
=365
 xH (B1.2)
where c denotes the number of births in Kenya, in 2006; z denotes the average number of births per female; UН denotes the
daily birth rate of humans; j denotes the proportion of Kenyan population that are female; ðlFlIÞ
xH
=
365
denotes the probability of
being of childbearing age; and xH denotes the expected human lifespan (days).B2. Movement from susceptible to exposed classes ðbH;iÞ
The expected rate of movement of humans from being susceptible to exposed to P. falciparum, during a blood meal when
sporozoites are introduced through the salivary gland of the female An. mosquito, is defined by
bH;i ¼ c Ti (B2.1)
where i denotes the P. falciparum strain (i ¼ w for SP-sensitive or i ¼ r for SP-resistant); c denotes the female An. mosquito
daily biting rate; and Ti denotes the transmission probability of strain i from mosquito to human.B3. Movement from exposed to infected ðsHÞ
The expected time to infectious gametocytes, y, in days is defined by
y ¼ PН þ GI þ GM (B3.1)
where PН denotes the latency period of asexual parasites in humans (days); GI denotes the time until the initial wave of
asexual P. falciparum (days); and GM denotes the time for gametocytes to mature in order to be infectious to female An.
mosquitoes (days).
Therefore, the rate of human movement from being exposed to P. falciparum (during a blood meal), to being infectious
(mature gametocytes), is given by
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1
y
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where y denotes the expected time to infectious gametocytes (days).
B4. Movement from infected to susceptible ðgi:dÞ
The estimated daily rate of recovery gi;d is defined by
gi;d ¼
1
PН þ hþ εi;d  y
(B4.1)
where i ¼ w for SP-sensitive P. falciparum, i ¼ r for SP-resistant P. falciparum, i ¼ wr for mixed P. falciparum infection; d ¼ q for
good quality AL treatment, d ¼ m for full-dose SP treatment, d ¼ p for half-dose SP treatment and d ¼ n for no antimalarial
treatment;PН denotes the latency period of asexual P. falciparum in humans (days); h denotes the delay in seeking treatment
(days); εi;d denotes the estimated time to recovery in days (see Appendix C2); and y denotes the expected time to infectious
gametocytes (days) (Eq. (B3.1)).
B5. Movement from infected to acquired immunity ðgRÞ
Immunity to malaria is defined by Bruce-Chwatt (1980) as “the state of resistance to infection brought about by all those
processes which are involved in destroying the plasmodia or by limiting their multiplication”, and can be passive or active.
Passive immunity is conferred from mother to child or through vaccinations (Doolan, Dobano, & Baird, 2009). For the pur-
poses of this model, we assume passive immunity cannot be gained. Actively acquired immunity is assumed to be temporarily
gained after continuous exposure, as used in the model by Labadin et al. (2009). Acquired immunity has been found to be
delayed in the presence of intermittent or prophylaxis treatment (Doolan et al., 2009), and additionally in full dose treatment,
as parasites are eradicated (Long, Nakazawa, Huaman,& Kanbara, 2002). In research carried out by Long et al. (2002) on mice,
lower doses of antimalarial treatment better enabled the mice to acquire protective immunity than the higher doses. We
assume that once acquired immunity is gained, protection is afforded against both SP-sensitive and SP-resistant infections.
The maximum expected rate of acquired immunity gained is defined by Eq. (B5.1) (Labadin et al., 2009), resulting in the
parameter range for gR of [0, 0.0018].
gR ¼
q s
qþ s (B5.1)
where gR denotes the rate acquired immunity is gained; q denotes the daily rate of building effective immunity; and s denotes
the daily rate of recovery.
B6. Human mortality rates (mO and mI)
The two different reported values for total human mortality in Kenya in 2006 are:
 The World Bank states 11 deaths per 1000 population, equating to a count of 404,332 deaths (The World Bank, 2006-
2013c).
 The WHO World Malaria Report states that there were 216,158 deaths in total, with 40,079 as a result of malaria (World
Health Organization, 2010b).
The difference in estimates of mortality provided by the World Bank and the WHO World Malaria Report indicates the
possibility of under-reporting in the estimates obtained by the WHO, for both overall and malaria-specific mortality. The
number of malaria deaths reported by the WHO was adjusted by an “under-reporting” factor calculated in Eq. (B6.1).
Estimated Malaria DeathsðcountÞ ¼ 40079
216158
 404332 ¼ 74970 (B6.1)The daily rate of mortality is defined into two groups: (i) malaria-specific mortality ðmIÞ and (ii) other mortality ðmOÞ.
Malaria-specificmortality occurs once humans are within the infected class; and other deaths occur in all other classes of the
model, where these non-malarial associated deaths may be due to other illnesses, old age, accidents, among other causes.
The calculation for the daily rate ofmalaria-specificmortality ðmIÞ is defined below. The proportion of those infected with P.
falciparum who die, x, in 2006 is
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Malaria Cases
¼ 0:0084 (B6.2)An estimate of the overall rate of recovery from infected to susceptible classes, g, at baseline is:
g ¼
X
i
Fi
X
d
qdgi;d
¼ Fw

qqgw;q þ qmgw;m þ qpgw;p þ qngn

þ Fr

qqgr;q þ qmgr;m þ qpgr;p þ qngn

þ Fwr

qqgwr;q þ qmgwr;m þ qpgwr;p
þ qngn

¼ 0:6821
(B6.3)Therefore, the daily rate of malaria-specific mortality ðmIÞ while the human is infected (i.e. has infectious gametocytes) is
approximately:
mI ¼ x
mH þ qngR þ g
1 x ¼ 0:0058 (B6.4)It must be noted that the estimate of malaria-specific mortality does not include the time period the patient is in the
exposed class and symptomatic (asexual P. falciparum) but not infectious (mature gametocytes). In addition to this, the
calculation formortality is affected by the percentage use of antimalarial medicines. For this reason, it was defined at the 2006
baseline and cannot be explored under different drug use scenarios (results section). Finally, this calculation assumes that the
“total population minus malaria cases” is an accurate estimate of the number of people who do not get malaria. It must be
noted that people can get more than one malaria infection within the calendar year.
The othermortality ðmOÞ is assumed to be approximately equal to the overall mortality rate in humans ðmHÞ, defined as 1/
(life expectancy), because the proportion of those with malaria who die is so small (see Eq. (B6.4)).
mH ¼
1
xH
¼ 1
56 365 ¼ 4:8924 10
5ymO (B6.5)C. Treatment parameters
The treatment-based model parameters are defined in Table C.1, along with the parameter values used, the parameter
range, and the published reference or the section of the Appendices where this parameter is defined.Table C.1
Treatment parameters. A description of the treatment parameters used in the model. For parameter values where literature values were readily available,
these values, along with the range of values and references are provided. For parameters that required further manipulation from the original source, the
section of the Appendices where this parameter is discussed is noted. All parameter units are in days, unless otherwise stated.
Symbol Parameter description Value [range or ±10%] Reference
1 qn Probability of receiving treatment 0.80 [0.80, 0.91] Chuma et al. (2007)
qn Receiving no treatment (proportion, at baseline) 0.20 [0.09, 0.20] Chuma et al. (2007)
qm Receiving full-dose SP monotherapy (proportion, at baseline) 0.07 [0.063, 0.077] Demographic and Health
Surveys (various) (2003
e2012)
qp Receiving half-dose SP monotherapy (proportion, at baseline) 0.03 [0.027, 0.33] Appendix C1
qq Receiving AL (proportion, at baseline) 0.70 [0.63, 0.77] Appendix C1
εw;q SP-sensitive gametocyte clearance in humans treated with AL 14 [12.6, 15.4] Appendix C2.1
εr;q SP-resistant gametocyte clearance in humans treated with AL 14 [12.6, 15.4] Appendix C2.1
εwr;q Mixed infection gametocyte clearance in humans treated with AL 14 [12.6, 15.4] Appendix C2.1
εw;m SP-sensitive gametocyte clearance in humans treated with full-dose SP
monotherapy
25 [21, 119] Appendix C2.2
εr;m SP-resistant gametocyte clearance in humans treated with full-dose SP
monotherapy
112 [112, 882] Appendix C2.2
εwr;m Mixed infection gametocyte clearance in humans treated with full-dose SP
monotherapy
25 [21, 119] Appendix C2.2
Table C.1 (continued )
Symbol Parameter description Value [range or ±10%] Reference
εw;p SP-sensitive gametocyte clearance in humans treated with half-dose SP
monotherapy
29 [29, 162] Appendix C2.2
εr;p SP-resistant gametocyte clearance in humans treated with half -dose SP
monotherapy
112 [112, 882] Appendix C2.2
εwr;p Mixed infection gametocyte clearance in humans treated with half -dose SP
monotherapy
92 [92, 772] Appendix C2.2
εn Gametocyte clearance in humans not treated 75 [0, 730] Anderson and May (1991)
Zw;q SP-sensitive gametocyte transmission when treated with AL (probability) 0.053705 [0.0183335,
0.053705]
Appendix C3.3
Zr;q SP-resistant gametocyte transmission when treated with AL (probability) 0.053705 [0.0183335,
0.053705]
Appendix C3.3
Zwr;q Mixed infection gametocyte transmission when treated with AL (probability) 0.053705 [0.0183335,
0.053705]
Appendix C3.3
Zw;m SP-sensitive gametocyte transmission when treated with full-dose
SP (probability)
0.055 [0.0495, 0.0605] Appendix C3.2
Zr;m SP-resistant gametocyte transmission when treated with full-dose
SP (probability)
0.3 [0.424485, 0.4999] Appendix C3.2
Zwr;m Mixed infection gametocyte transmission when treated with full-dose SP
(probability)
0.31 [0.452, 0.527375] Appendix C3.2
Zw;p SP-sensitive gametocyte transmission when treated with half-dose
SP (probability)
0.0489 [0.04401, 0.05379] Appendix C3.2
Zr;p SP-resistant gametocyte transmission when treated with half-dose
SP (probability)
0.0147 [0.0125, 0.0147] Appendix C3.2
Zwr;p Mixed infection gametocyte transmission when treated with half-dose
SP (probability)
0.1913 [0.1639, 0.1913] Appendix C3.2
Zn Gametocyte transmission with no treatment (probability) 0.2 [0.2, 0.5] Mandal et al. (2011),
Appendix C3.1
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Chuma et al. (2007) investigated treatment seeking behaviour of those residing in Kenya. During the two week period of
the study, the percentage of people with acute illnesses that did not use treatment was 9.3% in urban areas and 20.1% in rural
areas. Therefore, we parameterised the proportion of those who do not seek treatment ðqnÞ as ranging from 0.09 to 0.20. This
leads to the understanding that those who seek treatment ð1 qnÞ ranges from 0.80 to 0.91.
The 2003 Demographic Health Survey (DHS) was used to estimate the percentage of SP used within the community. The
survey reported the treatment practises of parents with children under five years old, and it was identified that 10.9% received
SP (Demographic and Health Surveys (various), 2003e2012).
Insight into the quality of antimalarial medicines, especially the percentage of falsified medicines, has been informed by
numerous studies; however, accurate estimates are hard to come by. In 2006, Newton et al. (2006) estimated the percentage
of falsified medicines ranges from 1% to 50% worldwide. An analysis of the WorldWide Antimalarial Resistance Network
database found that out of 9348 antimalarial medicines sampled, 30.1% failed chemical or packaging quality tests, of which:
39.3%were classified as falsified; 2.3% as substandardmedicines; and 58.3% poor quality without evidence available to classify
them as substandard or falsified (Tabernero et al., 2014). A study released in 2003, analysing the quality of SP tablets sold by
private wholesale pharmacies in Dar Es Salaam, Tanzania, found that 8/18 (44%) of SP samples failed assay tests for content
and dissolution tests (Minzi et al., 2003).
Following this evidence, the probability of receiving full-dose SP ðqmÞwas set to 0.07; the probability of receiving half-dose
SP ðqpÞwas set to 0.03; the probability of not receiving any antimalarial treatment ðqnÞwas set to 0.20; and the probability of
receiving AL treatment ðqqÞ was assumed to be the remainder (Eq. (C1.1)), at baseline.
qq ¼ 1

qm þ qp þ qn
	 ¼ 0:70 (C1.1)C2. Gametocyte clearance (days) post-treatment ðεi;dÞ
C2.1. Artemether-Lumefantrine treatment sought
In the literature, Bousema et al. (2006) found 16.0% (12 out of 75) of children treated with AL had gametocytemia on day;
and Sutherland et al. (2005) found 7.94% (30 out of 378) treated children were carriers of gametocytes on day 28 post-
treatment. However, Sawa et al. (2013) found an average of 5:5 days of gametocyte carriage post-treatment (95% CI:
3.6e8.5 days) of children treated with AL who remained asexual parasite free during follow-up.
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to the susceptible class, given that the number of humans carrying gametocytes past day 28 is small.
εw;q ¼ εr;q ¼ εwr;q ¼ 14 days½7;28 (C2.1.1)
where εi;d denotes the estimated days for gametocyte clearance post-treatment, for P. falciparum strain i and drug treatment
d; and the parameter range is denoted [minimum, maximum].
C2.2. Sulfadoxine-Pyrimethamine treatment sought
The data used to inform the asexual and gametocyte clearance rates when treated with SP were calculated using the
combination of mice data (pyrimethamine treatment) (Huijben et al., 2010b, 2013, 2010a) and human SP studies carried out in
South Africa (Barnes, Little, et al., 2008) and Columbia (Mendez et al., 2007). The mice studies researched the effect of py-
rimethamine (not in combinationwith sulfadoxine) on gametocyte densities and the length of infectivity over a maximum of
28 days (Huijben et al., 2010a, 2013). The experimental design was developed to simulate the emergence of resistance, using
two genetically distinct P. chabaudi clonal lineages in each study: drug-resistant AS12265 (pyr-1A) and drug-sensitive AJ5154
(Huijben et al., 2010a); and drug-susceptible clone AJ5p and pyrimethamine-resistant clone AS6p(pyr1A) (Huijben et al.,
2013). The experiment was carried out in six to eight week-old female C57Bl/6J laboratory mice, with treatment taking
place six days post-inoculation. In mixed infections, 106 pyrimethamine-sensitive parasites were inoculated, followed by ~25
pyrimethamine-resistant parasites five days after the experiment began, to simulate the emergence of resistance. The esti-
mates for half-dose SP treatments were calculated from experimental data using on 50% of a full dose of pyrimethamine
(Huijben et al., 2013) and 37.5% of a full dose of pyrimethamine (Huijben et al., 2010a). Figure C2.2.1 shows a summary of data
obtained.Fig. C2.2.1. The daily P. chabaudi gametocyte density in mice post-pyrimethamine treatment for (A) pyrimethamine-sensitive gametocytes, (B) pyrimethamine-
resistant gametocytes, and (C) mixed infection gametocytes. The purple line denotes the gametocyte density for a 100% pyrimethamine treatment. The green line
denotes the gametocyte density of 37.5% of a full dose of pyrimethamine treatment for (A) and 50% of a full dose of pyrimethamine treatment for (B) and (C). Data
provided by Huijben et al. (2013, 2010a, 2010b).Estimates for the expected gametocyte clearance time for humans in days, corresponding to each P. falciparum infection
type i when using half-dose SP monotherapy did not exist at the time of developing this model, so multiple studies and
assumptions were used to calculate these values. Estimates of the time to recover were calculated using Eq. (C2.2.1), where
the ratio of expected recovery time of mice treated with half-dose pyrimethamine to full-dose pyrimethamine treatment is
multiplied by the expected time to recovery in humans treated with full-dose SP. A summary of the parameter values ob-
tained from the human and mice studies are provided in Table C2.2.1.
εi;d ¼ EðHÞi;m 
EðMÞi;p
EðMÞi;m
(C2.2.1)where EðHÞi;m denotes the gametocyte clearance time in humans for each P. falciparum strain iwhen treatedwith full-dose SP,
as found by Barnes, Little, et al., 2008; EðMÞi;p or n denotes the gametocyte clearance time in mice for each P. chabaudi strain i
when treated with half-dose SP ðpÞ or no treatment ðnÞ, as found by Huijben et al. (2010a) (for i ¼ w) or Huijben et al. (2013)
(for i ¼ r or wr); and EðMÞi;m denotes the gametocyte clearance time in mice for each P. chabaudi strain iwhen treated with
full-dose pyrimethmaine, as found by Huijben et al. (2010a) (for i ¼ w) or Huijben et al. (2013) (for i ¼ r or wr).
Table C2.2.1
Summary findings from gametocyte clearance studies. Gametocyte clearance time in human and mice studies, along with the parameter range ([minimum,
maximum]), for SP-sensitive ðwÞ, SP-resistant ðrÞ andmixed infections ðwrÞ in humans (Barnes, Little, et al., 2008, Mendez et al., 2007); and pyrimethamine-
sensitive ðwÞ, pyrimethamine-resistant ðrÞ and mixed infections ðwrÞ in mice Huijben et al. (2013, 2010a, 2010b).
Strain ðiÞ Human Studies Mice Studies
Full-dose SP Full-dose SP Full-dose Pyrimethamine Half-dose Pyrimethamine
Drug Sensitive
ðwÞ
49 [21, 119] 14 11 15
Drug resistant ðrÞ 315 [112, 882] >28 22 22
Mixed Infection
ðwrÞ
315 [112, 882] e 22 18
Reference(s) Barnes, Little, et al.,
2008
Mendez et al.
(2007)
Huijben et al. (2013); Huijben et al. (2010a,
2010b)
Huijben et al. (2013); Huijben et al. (2010a,
2010b)
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([minimum, maximum]), is provided in Table C2.2.2.Table C2.2.2
Expected gametocyte clearance in humans (days). The expected clearance of P. falciparum gametocytes in humans, using a linear interpolation of SP
treatment in humans (Barnes, Little, et al., 2008) and pyrimethamine treatment in mice studies (Huijben et al., 2010b, 2013, 2010a), using Eq. (C2.2.1).
AEstimated using mice data where the 37.5% of a full-dose of pyrimethamine treatment used (Huijben et al., 2010b, 2010a), whereas estimates from 50% of a
full-dose of pyrimethamine treatment were used for the other parameter calculations (Huijben et al., 2013).
Strain ðiÞ Treatment ðdÞ
AL Full-dose SP monotherapy Half-dose SP monotherapy
Drug Sensitive ðwÞ 28 49 [21, 119] 67 [29, 162] A
Drug resistant ðrÞ 28 315 [112, 882] 315 [112, 882]
Mixed Infection ðwrÞ 28 315 [112, 882] 258 [92, 722]C3. Infectiousness of humans to mosquitoes ðZi;dÞ
Barnes, Watkins, et al., 2008 identified a log-sigmoidal relationship between gametocyte density and infectivity to
mosquitoes, with the probability of mosquito infection dependent on the prevalence, duration and density of gametocyte
carriage in the human host. They further discussed that the infectivity given a “particular antimalarial treatment can be
characterised as a function of blood gametocyte density and time, summing these over the acute and all subsequent
recrudescence of that infection”. Bousema et al. (2006) comment that the infectious mosquito reservoir determines the force
of infection.
C3.1. No treatment sought
When no treatment is sought the expected probability of transmission ðZnÞ is assumed equal for each infection type,
Zn ¼ Zw;n ¼ Zr;n ¼ Zwr;n ¼ 0:2; range : 0:2 0:5 ðMandal et al:;2011Þ (C3.1.1)C3.2. Sulfadoxine-Pyrimethamine treatment
No specific dataset exists to inform the effect of SP treatment on infectiousness, so multiple studies were used to calculate
estimates. A study carried out byMendez et al. (2007) was used to calculate the probability of gametocyte transmissionwhen
treated with full-dose SP monotherapy. The study recorded the proportion of infected mosquitoes with oocysts after treat-
ment with SP, and the infectivity of those with and without SP-conferring mutations were calculated using membrane
feeding assays. Resistance was defined as the presence of DHFR-51 and DHFR-108 SP resistance-conferring mutations.
Figure C3.2.1 shows the summary of the data produced in this study.
To calculate the expected probability of transmission from humans to mosquitoes, the area under the curvewas calculated
and then averaged over the number of days humans were found to be infectious (see Eq. (C3.2.1) and Fig. C3.2.1, results in
Table C3.2.1). The calculation assumes a uniform average transmission probability, not taking into account days that humans
are more “infectious” to mosquitoes than others; and that infectiousness to mosquitoes over the 28 day experimental period
is indicative of the infectiousness of gametocytes in humans to mosquitoes over the timeframe of gametocytes being present
(i.e. > 28 days).
Zw or r;m ¼
Z 28
0
f ðtÞw or r;m$dt
9
(C3.2.1)
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resistant (r) infections treated with SP monotherapy;
Z 28
0
f ðtÞw or r;m$dt denotes the area under the gametocyte density-
time curve, over 28 days; and 9 denotes the count of the number of days gametocytes are seen.Fig. C3.2.1. The proportion of infected mosquitoes when exposed to (A) SP-sensitive P. falciparum gametocytes, (B) SP-resistant P. falciparum gametocytes (108
mutants only) and (C) SP-resistant P. falciparum gametocytes (51 and 108 mutants), from infected humans over five years of age on the Pacific Coast of Columbia,
who were treated with SP monotherapy. Estimates obtained from Fig. 1 of Mendez et al. (2007). Note: length of data collection was 28 days.
Table C3.2.1
Total area of average gametocyte density in Fig. C3.2.1, produced using estimates from Mendez et al. (2007).
Strain Average gametocyte density
SP-sensitive ðwÞ 0.055
SP-resistant (r)108-mutatnt 0.424485
SP-resistant (r) 51 & 108 mutant 0.4999These estimates were then used to linearly interpolate the probability of transmission for mixed infections when full-dose
SP monotherapy is used, and for all infections when half-dose SP monotherapy is used. As with the calculations for game-
tocyte clearance (Appendix C2), raw mice data provided by Huijben et al. (2013) was used (Fig. C3.2.2 and Fig. C3.2.3).
Figure C3.2.2 shows that the mixed infection (dotted green line) appears to behave as the sum of the gametocyte densities of
the SP drug-sensitive (w, purple line) and SP drug-resistant (r, blue line).Fig. C3.2.2. The average gametocyte density per day in mice infected with P. Chabaudi and treated with pyrimethamine. The blue line denotes the
pyrimethamine-sensitive (W) gametocyte density associated with pyrimethamine treatment. In like manner, the red line denotes the pyrimethamine-resistant
(R) gametocyte density, and the green dotted line denotes the mixed infection (WR) gametocyte density. Data provided by Huijben et al. (2013).
Fig. C3.2.3. Average gametocyte density of P. Chabaudi infected mice with (A) pyrimethamine-sensitive gametocyte treated with full-dose pyrimethamine; (B)
pyrimethamine-sensitive gametocyte treated with half-dose pyrimethamine; (C) pyrimethamine-resistant gametocyte treated with full-dose pyrimethamine; (D)
pyrimethamine-resistant gametocyte treated with half-dose pyrimethamine; (E) mixed infection gametocyte treated with full-dose pyrimethamine; (F) mixed
infection gametocyte treated with half-dose pyrimethamine. These graphs are produced using data from Huijben et al. (2013).
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with the data simulation where the mice is first infected with SP drug-sensitive ðwÞ P. falciparum first, then SP drug-
resistant ðrÞ P. falciparum are added after treatment has resumed at a vastly reduced number, the transmission probabili-
ties, Zwr;m ¼ Zrw;m.
Assuming the probability of transmission is directly proportional to gametocyte density (Fig. C3.2.3 and Table C3.2.2), the
infectivity to mosquitoes is calculated by multiplying the “known” infectivity for treatment with full-dose SP for strain i, by
the ratio of gametocytes when treated with full- or half-dose pyrimethamine in the mice models (Huijben et al., 2010a, 2013),
see Eq. (C3.2.2). It must be noted, that initially 1 106 pyrimethamine-sensitive parasites were inoculated followed five days
later with ~25 pyrimethamine-resistant parasites. We believe this experiment skews some of the results below, however a
measure of the degree of skewing in uncertain. For this reason, we must clearly indicate that these values are our best
estimate.
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Z 28
0
f ðtÞi;p$dtZ 28
0
f ðtÞi;m$dt
(C3.2.2)where Zi;m denotes the infectiousness of humans to mosquitoes calculated using values from Mendez et al. (2007) (Eq.
(C3.2.1));
Z 28
0
f ðtÞi;p$dt denotes the area under curve of the P. falciparum gametocytes density of strain i, treated with half-
dose pyrimethamine ðaÞ from mice models (Huijben et al., 2013);
Z 28
0
f ðtÞi;m$dt denotes the area under curve of the P. fal-
ciparum gametocytes density of strain i, treated with full-dose pyrimethamine ðmÞ frommice models (Table C3.2.2) (Huijben
et al., 2010a, 2013).Table C3.2.2
The calculated total area of average gametocyte density in Fig. C3.2.3, produced using data from Huijben et al. (2013).
Strain Treatment
Full-dose pyrimethamine Half-dose pyrimethamine
Pyrimethamine-sensitive ðWÞ 4241.723 3769.852
Pyrimethamine-resistant ðRÞ 6698.292 197.569
Mixed infection ðWRÞ 10940.015 3967.421C3.3. Artemether-Lumefantrine treatment
In the literature, Bousema et al. (2006) found 3.6% (27 out of 750) of randomly selected children were infectious to
mosquitoes on day seven (Table C3.3.1), whereas the children tested over two years of agewere found to be 18.7% infectious to
mosquitoes. Sawa et al. (2013) found that 1.9% (42 out of 2292) of those treated with AL who had gametocytes were infectious
tomosquitoes on day seven post treatment (Table C3.3.2). In addition, Sutherland et al. (2005) found 0% (0 out of 195) children
treated with AL were infectious to mosquitoes on day 28. This data has been amalgamated to produce Fig. C3.3.1, which
explores the infectivity of children treated with AL over time.Fig. C3.3.1. Combining past studies results for gametocyte infectivity to mosquitoes following AL treatment in children, as reported by Bousema et al. (2006);
Sawa et al. (2013); Sutherland et al. (2005).
Table C2.3.3.1
Infectiousness of gametocytes to mosquitoes after AL and SP treatment. Percentage of mosquitoes that become infected in membrane-feeding assays using
blood samples from randomly selected children on day 7 post-treatment, by treatment arm. (Obtained from Table B.4 of Bousema et al. (2006).)
Treatment arm Infected mosquitoes, % (proportion) RR (95% CI)
SP 6.9 (52/750) 1
AL 3.6 (27/750) 0.52 (0.33e0.82)
Table C3.3.2
Infectiousness of gametocytes to mosquitoes after AL treatment. Gametocyte infectiousness among mosquitoes, by study arm. Blood samples taken on day 7
after initiation of treatment, with mosquitoes examined on day 7 after feeding. (Obtained from Table B.3 of Sawa et al. (2013).)
Variable Proportion of Participants (%)
Individuals participating in membrane-feeding assays, no. 77
Microscopy finding on feeding day
Gametocyte prevalence 4.2 (3/72)
Gametocyte density, gametocytes/mL, geometric mean (95% CI) 39.5 (18.2e85.4)
Pfs25 QT-NASBA finding on feeding day
Gametocyte prevalence 21.7 (5/23)
Individuals infecting  1 mosquito 31.1 (24/77)
Infected mosquitoes, % (proportion) 1.9 (44/2293)
Oocysts in infected mosquitoes, no., mean [range] 1.3 [1, 2]
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Zw;q ¼ Zr;q ¼ Zwr;q ¼ 0:05705 (C3.3.1)
where Zw; denotes the expected probability of transmission for SP-sensitive ðwÞ gametocytes from an infected human to
mosquito; and q denotes the percentage use of AL treatment;m denotes the percentage use of full-dose SP; and n denotes the
percentage who receive no treatment.
The line of best fit in Fig. C3.3.1 indicates a poor fitting line (low R2); however the calculated estimates of infectiousness are
consistent with a study by Mendez et al. (2007), where they found that SP-resistant parasites are 7e10 times more likely to
infect mosquitoes after SP treatment, compared to no resistance.
A summary of the expected probability of transmission of gametocytes of strain ðiÞ from human to mosquito during a
blood meal, given the human drug treatment ðdÞ received by the human, is provided in Table C3.3.3.Table C3.3.3
A summary of the expected probability of transmission of each P. falciparum strain ðiÞ from human to mosquito during a blood meal, given the antimalarial
treatment. ALow values believed to be a product of the experimental design to collect data.
Strain ðiÞ Treatment ðdÞ
AL ðqÞ Full-dose SP ðmÞ Half-dose SP ðpÞ No Treatment ðnÞ
SP-sensitive ðwÞ 0.05705 0.055 0.0489 0.200
SP-resistant ðrÞ
108 mutant 0.05705 0.424485 0.0125 A
58 & 108 mutant 0.4999 0.0147 A 0.200
Mixed infection (wr)
108 mutant 0.05705 0.452 0.1639 A
58 & 108 mutant 0.527375 0.1913 A 0.200D. Transmission parameters
The transmission-based model parameters are defined in Table D.1, along with the parameter values used, the parameter
range, and the published reference or the Appendix reference where this parameter is defined.Table D.1
Transmission parameters. A description of the transmission parameters used in the model. For parameter values where literature values were readily
available, these values, along with the range of values and references are provided. For parameters that required further manipulation from the original
source, the section of the Appendices where this parameter is discussed is noted. All parameter units are in days, unless otherwise stated.
Symbol Parameter description Value [range] Reference
c Biting rate of female An. Mosquitoes 0$ 4050 [0.01, 0.5] Anderson and May (1991); Mandal et al. (2011)
Tw SP-sensitive sporozoite transmission (probability) 0.2 [0.2, 0.5] Mandal et al. (2011)
Tr SP-resistant sporozoite transmission (probability) 0.2 [0.2, 0.5] Mandal et al. (2011)
~Zw Overall transmission of SP-sensitive gametocytes (probability) 0.1459 [0.1313, 0.1605] Appendix D2
~Zr Overall transmission of SP-resistant gametocytes (probability) 0.1410 [0.1269, 0.1551] Appendix D2
Pw Fitness cost of resistance 0.6 [0.54, 0.66] Appendix D1D1. Fitness cost in mosquito midgut ðPwÞ
The benefit that antimalarial resistance affords to a Plasmodium parasite may also cause a fitness cost (Fr€oberg et al., 2013).
A study conducted by Mharakurwaa et al. (2011) identified a prevalence between 2% and 12% of antifolate resistant P. fal-
ciparum in the midguts of Anopheles arabiensis mosquitoes, which they discussed was very low, when in comparison, there
was a high prevalence of resistance within the human population. In contrast, Costanzo and Hartl (2011) discusses that there
is no discernible cost associated with maintaining resistance afforded by highly resistant triple or quadruple mutations in P.
falciparum.
Themodel assumes that the female An.mosquito can only be infectedwith one strain of P. falciparum. In the occasionwhen
the mosquito feeds on a human containing a mixed infection, the probability of P. falciparum SP-sensitive gametocytes being
selected over SP-resistant gametocytes in the An. mosquitoes midgut is defined by Pw, and set to 0.60 (where 0  Pw  1).
This value for Pw assigns a small cost to resistance. This assumption was made in order to simplify the model.
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The overall probability of gametocyte transmission from human tomosquito, for each P. falciparum infection ðiÞ, treatment
ðdÞ combination, are as follows:
~Zw ¼
X
d
qdZw;d þ Pw
X
d
qdZwr;d (D2.1)
~Zr ¼
X
d
qdZr;d þ ð1 PwÞ
X
d
qdZwr;d (D2.2)
where ~Zw and ~Zr denote the overall expected probability of transmission of SP-sensitive ðwÞ and SP-resistant ðrÞ gametocytes
from human to mosquito, respectively; qd denotes the percentage of drug use for each treatment type, d (d ¼ q for AL, d ¼ m
for ful-dose SP, d ¼ p for half-dose SP, and d ¼ n for no treatment); Zw;d denotes the probability of SP-sensitive gametocyte
transmission under each treatment, d; Zr;d denotes the probability of SP-resistant gametocyte transmission under each
treatment, d; Zwr;d denotes the probability of a mixed infection gametocyte transmission under each treatment, d; and Pw
denotes the fitness cost (see Appendix D1).E. Mosquito parameters
The model parameters for the female An. mosquito are defined in Table E.1, along with the parameter values used, the
parameter range, and the published reference or the Appendix reference where this parameter is defined.Table E.1
Anopheles mosquito parameters. A description of the parameters specific to female An. mosquitoes used in the model. For parameter values where
literature values were readily available, these values, along with the range of values and references are provided. For parameters that required further
manipulation from the original source, the section of the Appendices where this parameter is discussed is noted. All parameter units are in days, unless
otherwise stated.
Symbol Parameter description Value [range] Reference
NM Initial ratio of mosquitoes to humans (humans ¼ 1) 0.87 [0.5, 40] Mandal et al. (2011)
xМ Average life span of a female Anopheles mosquito
in Kenya (days)
8e21 Labadin et al. (2009); Olayemi and Ande (2008);
Tchuinkam et al. (2010); Wanji et al. (2003)
mМ Daily mortality rate of female mosquitoes 0.0280 [0.05, 0.5] Mandal et al. (2011), Appendix E3
UМ Daily rate female An. mosquitoes reach adulthood 0.0280 [0.020, 0.27] Chitnisa et al. (2008); Labadin et al. (2009)
PМ Latent period of mosquitoes (days) 5 [5, 15] Mandal et al. (2011)
GМ Proportion of mosquitoes that are infected with P. falciparum 0.40 [0.38, 0.83] Mbogo et al. (2003)E1. Movement from susceptible to exposed ðbM;iÞ
The P. falciparum transmission rate of female An. mosquitoes becoming exposed to P. falciparum gametocytes during a
blood meal is defined by
bM;w ¼ c~Zw (E1.2)
bM;r ¼ c~Zr (E1.3)
where bM;w and bM;r denote the rate of female Anophelesmosquitoes becoming exposed to SP-sensitive ðwÞ and SP-resistant
ðrÞ P. falciparum, respectively; c denotes the daily biting rate of female An. mosquitoes; and ~Zw and ~Zr denote the overall
expected probability of transmission of SP-sensitive ðwÞ and SP-resistant ðrÞ gametocytes from human to mosquito,
respectively (defined in Appendix D2).E2. Movement from exposed to infected ðsMÞ
The daily rate of female An.mosquitoes movement from exposed to P. falciparum during a blood meal, to being infectious
(sporozoites in salivary glands), is given by Eq. (E2.1). The model assumes that infected female An. mosquito do not recover
from an infection due to their short lifespan, as assumed in many mathematical models (Mandal et al., 2011).
A.R. Brock et al. / Infectious Disease Modelling 2 (2017) 161e187 183sM ¼
1
PМ
¼ 0:0280 A½0:036;42:5 (E2.1)
where sM denotes the daily rate of female An. mosquitoes movement from exposed to infected; PМ denotes the latency
period for female Anopheles mosquitoes; and the range is defined [min, max].
A To stabilise the model, we had to use a value less than the ranges identified in the literature.E3. Mortality rates ðmMÞ
The mortality rate of female An. mosquitoes is assumed equal irrespective of P. falciparum infection status. In order to
stabilise the model, we had to use a value ðmМ ¼ 0:0280 Þ less than the ranges identified in the literature, a range of 0.05-0.5.F. Sensitivity analysis
The sensitivity analysis results are found in Table F.1, where parameters that inferred a change in the total proportion of SP-
resistant infections in the human population of greater than ±10% were considered to be significant.Table F.1
Sensitivity analysis results. The changes in the predicted percentage of SP resistant-containing infections in humans during 2006, due to changes in
parameter values. When required, values are reported to 4 d.p. A The literature parameter range is 0.020e0.27, however there were computational re-
strictions that only permitted a range of 0.020e0.1406 days for the sensitivity analysis.
Symbol Description Range (known range or ±10%) Percentage change
Baseline Minimum Maximum Minimum Maximum
NH Human population size (initial) 1 0.9 1.1 0.10 0.12
NM Ratio of mosquito to human population (initial) 0.87 0.5 40 0.32 20.55
Pw Fitness cost in mosquito midgut 0.6 0.5 0.7 5.12 6.60
mМ Mortality rate of female An. mosquitoes 0.028 0.0476 0.125 0.29 0.24
UМ Rate female An. mosquitoes reach adulthood 0.028 0.020 0.1406A 0.26 36.20
PМ Latent period of An. mosquitoes 5 5 15 0.00 0.20
DM Kenyan 2006 malaria deaths 74,970 67,473 82467 0.00 0.00
YM Kenyan 2006 malarial cases 8,926,058 8,033,452.2 9818663.8 0.00 0.00
UН Birth rate for humans 1.1349  104 1.0411  104 7.8811  104 0.00 0.11
mІ Rate of malarial mortality in humans 0.0011 0.0010 0.0012 0.00 0.00
mΟ Rate of “other” mortality in humans 3.1779  105 2.86  105 3.50  105 0.00 0.00
PН Latency period of asexual parasites in humans 9 9 14 0.00 0.04
GM Maturing of gametocytes 2 2 3 0.00 0.01
h Delay in seeking treatment 1 0 2 0.01 0.04
c Biting rate of female An. mosquitoes 0.405 0.01 0.5 0.19 1.43
Tw SP-sensitive sporozoite transmission (probability) 0.2 0.2 0.5 0.00 86.98
Tr SP-resistant sporozoite transmission (probability) 0.2 0.2 0.5 0.00 17.90
qn Receive no treatment (proportion, at baseline) 0.2 0.09 0.2 0.57 0.00
qm Receiving full-dose SP monotherapy (proportion, at baseline) 0.07 0.063 0.077 0.52 0.54
qp Receiving half-dose SP monotherapy (proportion, at baseline) 0.03 0.027 0.033 0.00 0.00
εw;q SP-sensitive gametocyte clearance in humans treated with AL 14 7 28 9.20 13.61
εr;q SP-resistant gametocyte clearance in humans treated with AL 14 7 28 15.52 8.65
εwr;q Mixed infection gametocyte clearance in humans treated with AL 14 7 28 0.05 0.04
εw;m SP-sensitive gametocyte clearance in humans treated with
full-dose SP monotherapy
25 21 119 0.52 1.56
εr;m SP-resistant gametocyte clearance in humans treated with
full-dose SP monotherapy
112 112 882 0.00 0.26
εwr;m Mixed infection gametocyte clearance in humans treated with
full-dose SP monotherapy
112 21 119 0.01 0.00
εw;p SP-sensitive gametocyte clearance in humans treated with
half-dose SP monotherapy
29 29 162 0.00 0.52
εr;p SP-resistant gametocyte clearance in humans treated with
half-dose SP monotherapy
112 112 882 0.00 0.12
εwr;p Mixed infection gametocyte clearance in humans treated with
half-dose SP monotherapy
92 92 772 0.00 0.00
εn Gametocyte clearance in humans not treated 75 30 720 0.04 0.02
Zw;q SP-sensitive gametocyte transmission when treated with
AL (probability)
0.0537 0.0183 0.0537 5.69 0.00
(continued on next page)
Table F.1 (continued )
Symbol Description Range (known range or ±10%) Percentage change
Baseline Minimum Maximum Minimum Maximum
Zr;q SP-resistant gametocyte transmission when treated with
AL (probability)
0.0537 0.0183 0.0537 5.69 0.00
Zwr;q Mixed infection gametocyte transmission when treated with AL
(probability)
0.0537 0.0183 0.0537 5.69 0.00
Zw;m SP-sensitive gametocyte transmission when treated with
full-dose SP monotherapy (probability)
0.055 0.0495 0.0605 0.11 0.11
Zr;m SP-resistant gametocyte transmission when treated with
full-dose SP monotherapy (probability)
0.3 0.4245 0.4999 2.30 3.58
Zwr;m Mixed infection gametocyte transmission when treated with
full-dose SP monotherapy (probability)
0.31 0.452 0.5274 0.56 0.87
Zw;p SP-sensitive gametocyte transmission when treated with
half-dose SP monotherapy (probability)
0.0489 0.0440 0.0538 0.05 0.04
Zr;p SP-resistant gametocyte transmission when treated with
half-dose SP monotherapy (probability)
0.0147 0.0125 0.0147 0.01 0.00
Zwr;p Mixed infection gametocyte transmission when treated with
half-dose SP monotherapy (probability)
0.1913 0.1639 0.1913 0.05 0.00
Zn Gametocyte transmission with no treatment (probability) 0.2 0.2 0.5 0.00 4.27
gR Rate of acquired immunity 6.0864  104 5.4778  104 6.6950  104 0.00 0.00
r Rate of loss of acquired immunity 0.0027 0.0024 0.0030 0.00 0.00
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There are key assumptions and limitations in the model that have an impact on the findings; these are discussed in detail
below.
G1. Estimating the transmissibility and infectiousness of gametocytes
The transmissibility of gametocytes is estimated from the duration and density of gametocyte carriage in humans over
time. A well-known property of SP is its propensity to increase gametogenesis, which in turn increases the transmission of P.
falciparum between humans andmosquitoes (Barnes, Little, et al., 2008, Bousema& Drakeley, 2011; Hastings, 2006). The data
to inform the asexual and gametocyte clearance rates were calculated using a combination of mice malaria data for pyri-
methamine (Huijben et al., 2010b, 2013, 2010a), with human SP studies carried out in South Africa (Barnes, Little, et al., 2008)
and Columbia (Mendez et al., 2007).
Themice studies looked at the effect of pyrimethamine (not in combinationwith sulfadoxine) on the gametocyte densities
and length of infectivity over a maximum of 28 days (Huijben et al., 2010a, 2013). In using these data, we had to assume that
the estimates provided from pyrimethamine are a fair approximation of the estimates that would occur when used in
combination with sulfadoxine.
We feel that the large differences in gametocyte densities and infectivity, as a result of half- and full-dose SP, are due to the
experimental design of the mice studies. The pyrimethamine-sensitive infections were simulated by the injected the mice
with sensitive parasites on Day One. Mixed infections had the same inoculation of pyrimethamine-sensitive parasites on Day
One, followed by the introduction a small number of pyrimethamine-resistant parasites (approximately 25 parasites) on Day
Five. In the pyrimethamine-resistant only studies, resistant parasites were inoculated on Day Five (25 parasites). Following
this, we expect that this experimental design drives the lower SP-resistant estimates for the probability of gametocyte
transmission from humans to mosquitoes ðZr;dÞ for each treatment type ðdÞ, calculated in Appendix C3.2. This limitation
highlights the need for more data in this field.
The infectiousness of SP-induced gametocytes may be less than gametocytes that differentiate without the stress of SP
treatment, as found with the infectiousness of SP-induced gametocytes when compared to chloroquine-induced gameto-
cytes. However, this decrease is thought to be offset by a higher prevalence and density of gametocytes following SP treat-
ment (Barnes &White, 2005).
For the above reasons, the accuracy of gametocyte-parameter estimates used in ourmodel are unknown but are thought to
underestimate the true value. An additional area of uncertainty in using these estimates was introduced by slight differences
in experimental design between the twomice studies, when calculating estimates for a half-dose SP monotherapy treatment.
These parameter estimates were calculated using data inwhich 50% of a full-dose of pyrimethamine (Huijben et al., 2013) and
37.5% of a full-dose of pyrimethamine (Huijben et al., 2010a) was used.
G2. Transmissibility in asymptomatic infections and acquired immunity
Both symptomatic and asymptomatic infections harbour gametocytes (Bousema et al., 2014). The ability to transmit
during asymptomatic infections are not included as they are outside of the scope of this study, as asymptomatic individuals
have no reason to seek antimalarial treatment.
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mosquitoes, in those with acquired immunity, in contrast to work carried out by Klein et al. (2008). We deemed this outside
the scope of the study, as these individuals also would not need to seek treatment. A summary of the effect of acquired
immunity on gametocyte density has been carried out by Carter and Graves (1988) and Bousema and Drakeley (2011). Both
papers surmise a conflict in findings by researchers; some conclude that patients with acquired immunity may be able to
control asexual parasite densities better, and hence have lower gametocyte densities. However, others have shown that
gametocyte densities may be at their highest in acquired immune populations. Bousema and Drakeley (2011) recommend
longitudinal studies to further explore this relationship. Additionally, we do not account for any passive (maternal) immunity
to malaria in infants.
G3. Patient adherence
Patient adherence is commonly identified as a confounding factor. In our case, SP is a single dose regimen, so we assumed
perfect patient adherence. Artemether-lumefantrine in adults requires 24 tablets administered over 3 days. However, the
model assumes that all AL treatment is of good quality, obtained from a reputable source and that all patients complete the
treatment regime. However, there have recently been severe problems with the quality of AL in Africa (Newton et al., 2014;
World Health Organization, 2015).
G4. Defining antimalarial resistance
The model assumes there is only one kind of resistance within the P. falciparum population, to SP. In reality, resistance has
emerged to nearly all antimalarial compounds currently in use, and molecular markers associated with AL resistance have
been described (Newton et al., 2014).
When defining SP resistance within our model, tolerance and low levels of resistance were excluded, but are expected to
have an impact on the spread of resistance in P. falciparum (Tchuenche et al., 2011).
G5. Mortality rates of mosquitoes
A constant mortality rate of mosquitoes was assumed, irrespective of P. falciparum-infection status, unlike the model
produced by Tchuenche et al. (2011). Our model also assumed that mosquitoes could not harbour a mixed infection ðwrÞ, and
that the selection of SP-sensitive over resistant gametocytes during the bloodmeal, proceeding through to the mosquito's
midgut and then salivary gland, occurs at Pw ¼ 0:6. In their work, Huijben, Sim, Nelson, and Read (2011) found that resistant
parasites are suppressed in the absence of treatment (irrespective of the number of competitors in multi-clonal environ-
ments), but have a marked advantage following drug treatment. They described a pattern of transient fitness advantage but it
did not appear to have an effect on the overall transmission potential. Costanzo and Hartl (2011) found no discernible cost
associatedwithmaintaining resistance afforded by highly resistant triple or quadruplemutations in P. falciparum. However, in
a study conducted by Mharakurwaa et al. (2011) a lower prevalence (2%e12%) of antifolate resistant parasites were found in
the midgut's of Anopheles arabiensis mosquitoes, when compared to the high prevalence of resistance within the human
population.
G6. Seasonality
Although the temporal resolution of the parameters were daily, the model outcomes were produced as yearly measures.
For this reason, seasonality was not accounted for within the model structure.
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